|
Terazosin
resources
|
|
|
|
|
|
DRUG INFO Terazosin
Drug Name:
Terazosin
Indication: For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension.
Pharmacology: Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an alpha-adrenergic blocking agent, terazosin is used to treat hypertension and benign prostatic hypertrophy (BPH). Terazosin produces vasodilation and reduces peripheral resistance but in general has slight effect on cardiac output. Antihypertensive effect with chronic dosing is usually not accompanied by reflex tachycardia.
Mechanism Of Action: Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia.
Drug Category: Antineoplastic Agents; Adrenergic alpha-Antagonists; Platelet Aggregation Inhibitors; ATC:G04CA03
Brand Names/Synonyms: Abbott 45975; Blavin; CHEMBANK1722; Flumarc; Fosfomic; Heitrin; Hytracin; Hytrin; Hytrinex; Itrin; Terazosin; Terazosin Hcl; Terazosin Hydrochloride; Terazosina [Inn-Spanish]; Terazosine; Terazosine [Inn-French]; Terazosinum [Inn-Latin]; Trazosin Hcl; Urodie; Vasocard; Vasomet; Vicard
Dosage Forms: TABLET
Absorption: Essentially completely absorbed in man (90% bioavailability).
Interactions:
DrugBank: Interactions for Terazosin
Interactions for Terazosin:
In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no
unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant
therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used
concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e.g.,
acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e.g., erythromycin, trimethoprim and
sulfamethoxazole); 3) anticholinergic/sympathomimetics (e.g., phenylephrine hydrochloride, phenylpropanolamine
hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e.g., allopurinol); 5) antihistamines (e.g.,
chlorpheniramine); 6) cardiovascular agents (e.g., atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7)
corti-costeroids; 8) gastrointestinal agents (e.g., antacids); 9) hypoglycemics; 10) sedatives and tranquilizers
(e.g., diazepam).
Use with Other Drugs
In a study (n=24) where terazosin and verapamil were administered concomitantly, terazosin’s
mean AUC0-24 increased 11% after the first verapamil dose and after 3 weeks of verapamil treatment it
increased by 24% with associated increases in Cmax (25%) and Cmin (32%) means. Terazosin mean
Tmax decreased from 1.3 hours to 0.8 hours after 3 weeks of verapamil treatment. Statistically significant
differences were not found in the verapamil level with and without terazosin. In a study (n=6) where terazosin and
captopril were administered concomitantly, plasma disposition of captopril was not influenced by concomitant
administration of terazosin and terazosin maximum plasma concentrations increased linearly with dose at steady-state
after administration of ter-azosin plus captopril.
Chemical IUPAC Name: [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone
Chemical Formula: C19H25N5O4
Half Life: 12 hours
Drug Type: Approved Drug
# Accession No: APRD00667
CAS Registry Number: 63590-64-7
|
|
|
|
|
|
Terazosin News (When available)
Reports Examine Dual Eligibles, Ways To Expand Health Coverage Dec 20, 2005 Kaiser network.org, Insurance Coverage for Those with High Medical Costs," Urban Institute: The brief, by Linda Blumberg, Lisa Clemans-Cope and Frederic Blavin, examines options ...
Expanding health coverage remains a daunting task Dec 30, 2005 SHRM Magazine, It was authored by institute economist Linda J. Blumberg and research associates Lisa Clemans-Cope and Fredric Blavin. Blumberg ...
Trendy New Water-Bottle Labels Use Artwork, Conservation Messages ... Dec 13, 2005 Business Wire (press release), Mrs. Maas Long Beach USD Las Virgenes Kevin Adams 3 Sumac Elem. Mr. Tally Las Virgenes USD Liz Itrin 5 Chaparral Mrs. Brinkman Las Elem. ...
|
|
|